09688.HK
Zai Lab Limited
HKSE · Healthcare · Biotechnology · CN
HKD 20.76
−1.42%Year over year
Reported trailing growth
- Revenue
- +5.0%
- EBITDA
- -4.5%
- EBIT
- -6.8%
- EPS
- +70.4%
- Free cash flow
- +41.7%
- Operating cash flow
- +27.4%
Forward estimates
Based on analyst estimates
- Revenue
- +3.2%
- EBITDA
- -7.7%
- EPS
- -26.1%
Three-year CAGR
- Revenue
- +28.9%
- EBITDA
- +15.3%
- EBIT
- +18.6%
- Net income
- +31.6%
- EPS
- +38.5%
- Free cash flow
- +42.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026